Details of Disease

Disease Name

Peritoneal neoplasm

neoplasm of peritoneum; peritoneum tumor; tumor of peritoneum; peritoneum tumour; tumour of peritoneum; peritoneal neoplasm; peritoneum neoplasm (disease); peritoneum neoplasm

Definition

A benign or malignant neoplasm that affects the peritoneal cavity. Representative examples of benign neoplasms include adenomatoid tumor and disseminated peritoneal leiomyomatosis. Representative examples of malignant neoplasms include primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma.

Disease Hierarchy

DISTBY9Z: Tumour

DIS2ZMIF: Peritoneal neoplasm

Disease Identifiers

MONDO ID

MONDO_0006901

MESH ID

D010534

UMLS CUI

C0031149

MedGen ID

18392

SNOMED CT ID

126865007

General Information of Disease (ID: DIS2ZMIF)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Irinotecan	DMP6SC2	Approved	Small molecular drug	[1]
Oxaliplatin	DMQNWRD	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MCAM	TTHRE05	Strong	Biomarker	[3]
MLANA	TT362RB	Strong	Biomarker	[3]
MUC1	TTBHFYQ	Strong	Biomarker	[3]
SLC2A1	TT79TKF	Strong	Biomarker	[3]
WT1	TTZ8UT4	Strong	Biomarker	[3]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CALB2	OTSNMCG9	Strong	Biomarker	[3]
IGF2BP3	OTB97VIK	Strong	Biomarker	[4]
PDPN	OTBUV19I	Strong	Biomarker	[3]
------------------------------------------------------------------------------------

References

1	Irinotecan FDA Label
2	Oxaliplatin FDA Label
3	Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.Ann Diagn Pathol. 2013 Feb;17(1):99-103. doi: 10.1016/j.anndiagpath.2012.05.007. Epub 2012 Jul 10.
4	CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma.Cancer Sci. 2013 Aug;104(8):989-95. doi: 10.1111/cas.12185. Epub 2013 May 26.